2 recruiting, 1 active not recruiting, 1 completed. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 2, Active not recruiting 1, Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow bulevirtide: new trials by email Literature Review of bulevirtide trials Research Report on bulevirtide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Brelovitug (BJT-778), Bulevirtide - Chronic Hepatitis D | Phase 2 / Phase 3 | Recruiting | Mirum Pharmaceuticals, Inc. | 120 | 2026-02-26 | 2026-10-27 |
| A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mg - Chronic Hepatitis D Infection | Phase 3 | Recruiting | Mirum Pharmaceuticals, Inc. | 172 | 2025-08-27 | 2026-10-08 |
| A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide Tobevibart, Elebsiran, Bulevirtide - Viral Hepatitis | Phase 3 | Active not recruiting | Vir Biotechnology, Inc. | 150 | 2025-07-30 | 2026-07-13 |
| Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD) Bulevirtide - Chronic Hepatitis Delta | Phase 3 | Completed | Gilead Sciences | 150 | 2019-04-17 | 2025-08-22 |
Hepatitis D, Chronic (3) · Hepatitis D (2) · Digestive System Diseases (1) · Hepatitis (1) · Liver Diseases (1)
Mirum Pharmaceuticals, Inc. (2) · Gilead Sciences (1) · Vir Biotechnology, Inc. (1)
Germany (4) · Italy (4) · Austria (3) · France (3) · Romania (3) · Spain (3) · United Kingdom (3) · Czechia (2) · Sweden (2) · Pakistan (1) · Russia (1) · Switzerland (1) · United States (1) · Uzbekistan (1)
PMID 37120031, PMID 38340811, PMID 39009085, PMID 39648559, PMID 41405233, PMID 41586499, PMID 41966308
2019 (1)